問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

劉宗灝LIU, TSUNG-HAO
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • thliu@ntuh.gov.tw

Recruiting Trial

97Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉宗灝

List

115Cases

2021-10-18 - 2026-11-22

Phase III

Active
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER

  • Condition/Disease

    Neoplasms

  • Test Drug

    膠囊劑 注射劑 注射劑 注射劑 注射劑 注射劑 注射劑 錠劑 輸注液

Participate Sites
8Sites

Recruiting8Sites

2026-01-15 - 2031-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2024-09-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-11-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2019-11-01 - 2024-05-13

Phase II

Completed
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Erdafitinib

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting5Sites

Terminated6Sites

2024-04-01 - 2028-01-31

Phase I

Active
A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

Terminated1Sites

2023-06-01 - 2027-12-31

Phase I/II

Active
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

  • Condition/Disease

    Advanced or metastatic solid malignancy

  • Test Drug

    AZD8205

Participate Sites
5Sites

Recruiting5Sites

2024-06-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-04-02 - 2025-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2025-05-01 - 2028-12-31

Phase I/II

Active
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)

  • Condition/Disease

    (1)To investigate the safety and tolerability of AZD9793 monotherapy in participants with advanced or metastatic solid tumors expressing Glypican 3 (GPC3), and to determine the Maximum Tolerated Dose (MTD), Optimal Biological Dose (OBD), and/or Recommended Dose for Expansion (RDE), and the Recommended Phase 2 Dose (RP2D).(2)To evaluate the preliminary anti-tumor activity of AZD9793 monotherapy in participants with advanced or metastatic solid tumors expressing GPC3.

  • Test Drug

    AZD9793

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4 5 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB